A randomized, double-blind, single-dose, two-way, parallel phase I clinical study comparing the pharmacokinetics and safety of adalimumab injecta and Humira® in healthy Chinese male volunteers

References

• Kang J, Eudy-Byrne RJ, Mondick J, et al. Population pharmacokinetics of adalimumab biosimilar adalimumab-adbm and reference product in healthy subjects and patients with rheumatoid arthritis to assess pharmacokinetic similarity. Brit J Clin Pharmaco. 2020. DOI: 10.1111/bcp.14330.
   PubMedGoogle Scholar
• Chen L, Huang ZC, Liao Y, et al. Association between tumor necrosis factor polymorphisms and rheumatoid arthritis as well as systemic lupus erythematosus: a meta-analysis. Braz J Med Biol Res. 2019;52(3). DOI: 10.1590/1414-431x20187927.
   Web of Science ®Google Scholar
• Liu C, He L, Wang J, et al. Anti-angiogenic effect of Shikonin in rheumatoid arthritis by downregulating PI3K/AKT and MAPKs signaling pathways. J Ethnopharmacol. 2020;260:113039.
   PubMed Web of Science ®Google Scholar
• Kholodenko RV, Kalinovsky DV, Doronin II, et al. Antibody Fragments as Potential Biopharmaceuticals for Cancer Therapy: success and Limitations. Curr Med Chem. 2019;26(3):396–426.
   PubMed Web of Science ®Google Scholar
• Parslow AC, Parakh S, Lee FT, et al. Antibody-Drug Conjugates for Cancer Therapy. Biomedicines 2016;4(3). DOI: 10.3390/biomedicines4030014
   PubMedGoogle Scholar
• Lombardi G, Perego S, Sansoni V, et al. Anti-adalimumab antibodies in psoriasis: lack of clinical utility and laboratory evidence. BMJ Open. 2016;6(12):e011941.
   PubMed Web of Science ®Google Scholar
• Bridgen A, Dalrymple DA, Weber F, et al. Inhibition of Dugbe nairovirus replication by human MxA protein. Virus Res. 2004;99(1):47–50.
   PubMed Web of Science ®Google Scholar
• Grossi V, Infantino M, Manfredi M, et al. Anti-adalimumab and anti-certolizumab antibodies titers after discontinuation of adalimumab: two case reports. Clin Chem Lab Med. 2020;58(4):e105–e8.
   PubMed Web of Science ®Google Scholar
• Puri A, Niewiarowski A, Arai Y, et al. Pharmacokinetics, safety, tolerability and immunogenicity of FKB327, a new biosimilar medicine of adalimumab/Humira, in healthy subjects. Br J Clin Pharmacol. 2017;83(7):1405–1415.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Mizoshita T, Sugiyama T, et al. Adalimumab Dose-Escalation Therapy Is Effective in Refractory Crohn’s Disease Patients with Loss of Response to Adalimumab, Especially in Cases without Previous Infliximab Treatment. Case Rep Gastroenterol. 2019;13(1):37–49.
   PubMedGoogle Scholar
• Oh EH, Kim J, Ham N, et al. Long-term Outcomes of Adalimumab Therapy in Korean Patients with Ulcerative Colitis: a Hospital-Based Cohort Study. Gut Liver. 2020;14(3):347–356.
   PubMed Web of Science ®Google Scholar
• Wouters OJ, Kanavos PG, Mckee M. Comparing Generic Drug Markets in Europe and the United States: prices, Volumes, and Spending. Milbank Q. 2017;95(3):554–601.
   PubMed Web of Science ®Google Scholar
• Wynne C, Altendorfer M, Sonderegger I, et al. Bioequivalence, safety and immunogenicity of BI 695501, an adalimumab biosimilar candidate, compared with the reference biologic in a randomized, double-blind, active comparator phase I clinical study (VOLTAIRE (R)-PK) in healthy subjects. Expert Opin Inv Drug. 2016;25(12):1361–1370.
   PubMed Web of Science ®Google Scholar
• Park KR, Chung H, Yang SM, et al. A randomized, double-blind, single-dose, two-arm, parallel study comparing pharmacokinetics, immunogenicity and tolerability of branded adalimumab and its biosimilar LBAL in healthy male volunteers. Expert Opin Inv Drug. 2017;26(5):619–624.
   PubMed Web of Science ®Google Scholar
• Hyland E, Mant T, Vlachos P, et al. Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira((R)) in healthy subjects. Br J Clin Pharmacol. 2016;82(4):983–993.
   PubMed Web of Science ®Google Scholar
• Shin D, Lee Y, Kim H, et al. A randomized phase I comparative pharmacokinetic study comparing SB5 with reference adalimumab in healthy volunteers. J Clin Pharm Ther. 2017;42(6):672–678.
   PubMed Web of Science ®Google Scholar
• Hillson J, Mant T, Rosano M, et al. Pharmacokinetic equivalence, comparable safety, and immunogenicity of an adalimumab biosimilar product (M923) to Humira in healthy subjects. Pharmacol Res Perspect. 2018;6(1). DOI: 10.1002/prp2.380.
   Google Scholar
• Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein Product to a Reference Product. [cited 2015 Apr]. Available from: http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm
   Google Scholar
• Committee for Medicinal Products for Human Use (CHMP). Guideline on Similar Biological Medicinal Products Containing Monoclonal Antibodies. Biotechnol Law Rep. 2011;30(2):235–242.
   Web of Science ®Google Scholar
• Cao GY, Yu JC, Wu JF, et al. A Randomized, Double-Blind, Parallel-Group, Phase 1 Clinical Trial Comparing the Pharmacokinetic, Safety, and Immunogenicity of the Biosimilar HS016 and the Originator Adalimumab in Chinese Healthy Male Subjects. Clin Pharm Drug Dev. 2020;10(3):317-325.
   PubMed Web of Science ®Google Scholar
• Hettema W, Wynne C, Lang B, et al. A randomized, single-blind, Phase I trial (INVICTAN-1) assessing the bioequivalence and safety of BI 695502, a bevacizumab biosimilar candidate, in healthy subjects. Expert Opin Inv Drug. 2017;26(8):889–896.
   PubMed Web of Science ®Google Scholar
• Shennak M, Al-Jaouni R, Kshirasagar S, et al. An Open-Label, Randomized, Single-Dose, Crossover, Comparative Pharmacokinetics Study of YLB113 and the Etanercept Reference Product in Healthy Adult Male Subjects. Eur J Drug Metab Pharmacokine. 2020;45(4):467–475.
   PubMed Web of Science ®Google Scholar
• Pivot X, Deslypere JP, Park LS, et al. A Randomized Phase I Study Comparing the Pharmacokinetics of HD201, a Trastuzumab Biosimilar, With European Union-sourced Herceptin. Clin Ther. 2018;40(3):396–405.
   PubMed Web of Science ®Google Scholar
• Yin D, Barker KB, Li R, et al. A randomized phase 1 pharmacokinetic trial comparing the potential biosimilar PF-05280014 with trastuzumab in healthy volunteers (REFLECTIONS B327-01). Br J Clin Pharmacol. 2014;78(6):1281–1290.
   PubMed Web of Science ®Google Scholar